Clinical Trial Update: JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC [Phase 1]

View source ↗

Summary

This document provides an update on a Phase 1 trial evaluating JAB-21822 in combination with chemotherapy and bevacizumab for second-line KRAS G12C colorectal c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• JAB-21822

Snippet

Sponsor: Jian Li | Conditions: Colorectal Cancer | Phase 1 | Status: ACTIVE_NOT_RECRUITING